| 1 |
35394121 | The prevalence and real-world therapeutic analysis of Chinese patients with KRAS-Mutant Non-Small Cell lung cancer. | 2022 Apr 8 |
1 |
| 2 |
34183390 | Cisplatin and Pemetrexed Have Distinctive Growth-inhibitory Effects in Monotherapy and Combination Therapy on KRAS-dependent A549 Lung Cancer Cells. | 2021 Jul-Aug |
3 |
| 3 |
34799908 | P1-38: Impact of cisplatin and pemetrexed on VEGFR-1 on inducing anticancer effects in KRAS-dependent A549 cells. | 2021 Nov |
1 |
| 4 |
31332704 | Clinical outcomes to pemetrexed-based versus non-pemetrexed-based platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. | 2020 May |
5 |
| 5 |
32236605 | CDKN1A upregulation and cisplatin‑pemetrexed resistance in non‑small cell lung cancer cells. | 2020 Jun |
1 |
| 6 |
31431614 | HSP90/AXL/eIF4E-regulated unfolded protein response as an acquired vulnerability in drug-resistant KRAS-mutant lung cancer. | 2019 Aug 20 |
1 |
| 7 |
27876675 | A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer. | 2017 Mar |
1 |
| 8 |
28407465 | KRAS G12C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer. | 2017 May |
2 |
| 9 |
26977001 | The Prognostic Role of KRAS Mutation in Patients with Advanced NSCLC Treated with Second- or Third-line Chemotherapy. | 2016 Mar |
2 |
| 10 |
23724098 | Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer. | 2013 |
1 |
| 11 |
22783588 | The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines. | 2012 |
1 |